Skip to main content

Connective tissue diseases

Systemic sclerosis

02-12-2022 | Systemic sclerosis | News

Anti-SSSCA1 positivity tied to cancer risk in SSc patients

Study findings reported in Rheumatology suggest that anti-SSSCA1 antibodies may warrant further investigation as a biomarker for cancer risk among patients with systemic sclerosis.

17-11-2022 | ACR 2022 | Conference coverage | News

New score could predict ILD development in people with SSc

Researchers have developed the ILD-RISC score, which has the potential to predict the development of interstitial lung disease in patients with systemic sclerosis.

14-10-2022 | Systemic sclerosis | News

Men may have a more severe SSc-ILD disease course than women

Men with systemic sclerosis-associated interstitial lung disease may experience worse outcomes than women, which could be explained by sex differences in biomarker profiles, suggests a post-hoc analysis of the SLS I and SLS II trials.

04-10-2022 | Systemic sclerosis | News

Elevated risk for osteoporotic fractures in women with SSc

Findings from two studies suggest that more attention may need to be given to the prevention of osteoporotic fractures among women with systemic sclerosis.

14-09-2022 | Systemic sclerosis | News

Systemic sclerosis linked to increased risk for heart failure

People with systemic sclerosis have an approximately threefold increased risk for clinically evident heart failure compared with the general population, suggest the results of a cohort study.

Clogged Artery, Arteriosclerosis Cholesterol plaque. 3d illustration

01-09-2022 | Cardiovascular disease | News

CV risk reduction should be ‘an integral part’ of autoimmune disease management

A large study published in The Lancet has found that people with autoimmune diseases have an approximately 1.4–3.6-fold increased risk for developing cardiovascular disease relative to the general population.

08-08-2022 | Systemic sclerosis | News

Impaired right ventricular function could signal high risk for poor outcomes in SSc patients

Measures of right ventricular function could provide “crucial information” to predict which patients with systemic sclerosis are at high risk for poor outcomes, researchers report in Arthritis Research & Therapy.

21-02-2022 | Cardiovascular disease | News

EULAR releases recommendations on CV risk management in RMD patients

EULAR has issued recommendations for managing cardiovascular risk in people with antiphospholipid syndrome, gout, mixed connective tissue disease, myositis, Sjögren’s syndrome, systemic lupus erythematosus, systemic sclerosis, or vasculitis.

17-02-2022 | Cardiovascular disease | News

Premature coronary artery disease risk increased with IMIDs

Individuals with certain immune-mediated inflammatory diseases are at increased risk for premature coronary artery disease, show population-based study data from Taiwan.

Rituximab and rheumatology practice in the COVID-19 era

Rituximab and rheumatology practice in the COVID-19 era

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?

17-12-2021 | Systemic sclerosis | News

VEDOSS criteria may help predict progression from Raynaud’s to SSc

Risk stratification using VEDOSS criteria can help identify individuals with Raynaud’s phenomenon who are most likely to progress to definite systemic sclerosis, study findings indicate.

03-12-2021 | Systemic sclerosis | News

Targeting pain should be a priority in systemic sclerosis

Pain affects almost nine in every 10 people with systemic sclerosis, with multiple disease-related factors potentially contributing to pain intensity, researchers report.

Chart and magnifying glass

18-11-2021 | Rheumatoid arthritis | News

Excess mortality gap closing, but not for all rheumatic diseases

Individuals with rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis have almost comparable survival rates to those of the general population, Greek study findings indicate.

Anifrolumab for the treatment of lupus

Anifrolumab for the treatment of SLE

Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

New additions to the Adis Journal Club

Adis Journal Club

A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

JAK inhibitor safety

Data summary, expert discussion, & research news on the potential risks associated with JAK inhibitors.

IV injection

24-06-2021 | Systemic sclerosis | News

DESIRES trial demonstrates promise for rituximab in systemic sclerosis

Findings from the DESIRES trial suggest that patients with systemic sclerosis derive significant improvements in skin sclerosis and lung function from treatment with rituximab.

04-06-2021 | EULAR 2021 | Conference coverage | News

Background mycophenolate may affect lenabasum efficacy in dcSSc

Primary analysis of the phase 3 RESOLVE-1 trial fails to show efficacy with lenabasum in patients with diffuse cutaneous systemic sclerosis.